DFTX

Definium Therapeutics Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↓ 1/10
  • Value↑ 5/10
Definium Therapeutics sales and earnings growth
DFTX Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -162.11%
  • FCF Y/Y↓ -57.45%
Definium Therapeutics gross and profit margin trends
DFTX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 203.88%
Definium Therapeutics net debt vs free cash flow
DFTX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -37.8

Definium Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks